01:00 PM - 01:15 PM

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Location: Le Meridian AL Khobar, Saudi Arabia

Social Share

× How can I help you?